Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH403905D
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ignyta Inc (Ignyta), formerly NexDx Inc, is a biotechnology company which discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. It develops products using integrated therapeutic (Rx) and companion diagnostic (Dx) platform. The company's clinical pipeline includes selective tyrosine kinase inhibitor of the TrkA, TrkB, TrkC, ROS1 and ALK protein and a small molecule inhibitor of BRAF, EGFR and RET. Ignyta's other pipeline products encompasses taladegib, a small molecule hedgehog/smoothened antagonist; RXDX-105, a small molecule multikinase inhibitor and RXDX-106, a small molecule, pseudo-irreversible inhibitor of TYRO3, AXL and Mer. The company also develops Trailblaze Diagnostic Programs. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Ignyta Inc, Medical Devices Deals, 2011 to YTD 2017 10

Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Ignyta Acquires Four Oncology R&D Assets from Cephalon 12

Venture Financing 13

NexDx Raises US$5.5 Million In Series B Financing 13

Partnerships 14

Ignyta Enters into Research Agreement with Moffitt Cancer Center 14

Merger 15

Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 15

Licensing Agreements 15

Ignyta Amends Licensing Agreement with Eli Lilly 15

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 16

Ignyta Enters into Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 18

Ignyta Enters Into Licensing Agreement With Nerviano Medical Sciences For Tyrosine Kinase Inhibitors 19

Equity Offering 20

Ignyta Raises USD57.5 Million in Public Offering of Shares 20

Ignyta Raises USD30 Million in Private Placement of Shares 21

Ignyta Raises USD75 Million in Public Offering of Shares 22

Ignyta Raises USD42 Million in Private Placement of Shares 24

Ignyta Completes Public Offering Of Shares For US$55.2 Million 25

Ignyta Completes Private Placement Of Shares For US$7.8 Million 26

Ignyta Completes Private Placement Of Shares For US$46.2 Million 27

Acquisition 28

Ignyta Acquires Actagene Oncology 28

Ignyta Inc-Key Competitors 29

Key Employees 30

Locations And Subsidiaries 31

Head Office 31

Recent Developments 32

Strategy And Business Planning 32

Feb 23, 2016: Ignyta Announces Strategic Positioning that Focuses on Prioritized Pipeline 32

Jan 11, 2016: Ignyta Unveils "5X5" Goal and Announces 2016 Strategic Priorities 33

Financial Announcements 34

Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 34

Nov 07, 2016: Ignyta Announces Third Quarter 2016 Company Highlights and Financial Results 36

Aug 09, 2016: Ignyta Announces Second Quarter 2016 Company Highlights and Financial Results 37

May 10, 2016: Ignyta Announces First Quarter 2016 Company Highlights and Financial Results 39

Mar 14, 2016: Ignyta Announces 2015 Full Year Company Highlights and Financial Results 41

Corporate Communications 44

Dec 12, 2016: Ignyta appoints new board member 44

Dec 12, 2016: Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals to Board of Directors 45

Product News 46

12/02/2016: Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting 46

11/15/2016: Ignyta Announces EAP Designation and CE Marking for its Trailblaze Pharos Clinical Trial Assay 47

Clinical Trials 48

Mar 03, 2017: Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific 48

Feb 09, 2017: Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery 49

Nov 29, 2016: Ignyta to Present Pre-clinical Data on Entrectinib at the 2016 EORTC-NCI-AACR Annual Meeting 51

Aug 31, 2016: Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial 52

Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting 53

Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56

List of Figures

Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Ignyta Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ignyta Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Ignyta Inc, Medical Devices Deals, 2011 to YTD 2017 10

Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Ignyta Acquires Four Oncology R&D Assets from Cephalon 12

NexDx Raises US$5.5 Million In Series B Financing 13

Ignyta Enters into Research Agreement with Moffitt Cancer Center 14

Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 15

Ignyta Amends Licensing Agreement with Eli Lilly 15

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 16

Ignyta Enters into Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 18

Ignyta Enters Into Licensing Agreement With Nerviano Medical Sciences For Tyrosine Kinase Inhibitors 19

Ignyta Raises USD57.5 Million in Public Offering of Shares 20

Ignyta Raises USD30 Million in Private Placement of Shares 21

Ignyta Raises USD75 Million in Public Offering of Shares 22

Ignyta Raises USD42 Million in Private Placement of Shares 24

Ignyta Completes Public Offering Of Shares For US$55.2 Million 25

Ignyta Completes Private Placement Of Shares For US$7.8 Million 26

Ignyta Completes Private Placement Of Shares For US$46.2 Million 27

Ignyta Acquires Actagene Oncology 28

Ignyta Inc, Key Competitors 29

Ignyta Inc, Key Employees 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ignyta Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com